<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92390">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01874054</url>
  </required_header>
  <id_info>
    <org_study_id>SGN35-016</org_study_id>
    <nct_id>NCT01874054</nct_id>
  </id_info>
  <brief_title>Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma</brief_title>
  <official_title>A Phase 1/2 Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and efficacy of brentuximab vedotin in
      combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It
      is an open-label, 2-stage study designed to determine the recommended dose level of
      bendamustine in combination with brentuximab vedotin. The study will assess the safety
      profile of the combination treatment and determine what proportion of patients achieve a
      complete remission.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose-limiting toxicities</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Through 1 month following last dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Participants will be followed for an average of 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Participants will be followed for an average of 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>Brentuximab Vedotin + Bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brentuximab vedotin 1.8mg/kg every 3 weeks and bendamustine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brentuximab vedotin</intervention_name>
    <description>1.8 mg/kg every 3 weeks by intravenous (IV) infusion</description>
    <arm_group_label>Brentuximab Vedotin + Bendamustine</arm_group_label>
    <other_name>Adcetris; SGN-35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bendamustine</intervention_name>
    <description>90 mg/m2 on Days 1 and 2 of 3-week cycles</description>
    <arm_group_label>Brentuximab Vedotin + Bendamustine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathological diagnosis of classical Hodgkin lymphoma

          -  Failed standard front-line therapy

          -  Measurable disease of at least 1.5 cm as documented by radiographic technique

          -  Eastern Cooperative Oncology Group performance status less than or equal to 2

        Exclusion Criteria:

          -  Received prior salvage therapy, including radiotherapy

          -  Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not
             completed 4 weeks prior to first dose of study drug

          -  Concurrent use of other investigational agents
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Josephson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Terri Lowe</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kinley Hurst</last_name>
      <phone>205-975-9481</phone>
      <email>mkhurst@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Andres Forero-Torres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Hematology Oncology Associates</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madeline Decker</last_name>
      <email>DeckerM@cpmcri.org</email>
    </contact>
    <investigator>
      <last_name>Caroline Behler, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sipra Choudhury</last_name>
      <phone>650-736-2563</phone>
      <email>schoudhury@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Ranjana Advani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Hope &amp; Innovation, The</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino</last_name>
      <phone>562-693-4477</phone>
      <email>kbettino@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Eric Cheung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Younger</last_name>
      <phone>720-754-4827</phone>
      <email>leslie.younger@healthonecares.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Matous, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Bernadin Cancer Center / Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Fahey</last_name>
      <phone>708-327-3228</phone>
      <email>kfahey@lumc.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Smith, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Francis Medical Group Oncology &amp; Hematology Specialists</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reba Baker</last_name>
      <phone>317-528-4481</phone>
      <email>reba.baker@franciscanalliance.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Eric Rubenstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Cowen</last_name>
      <phone>617-582-7292</phone>
      <email>LeslieF_Cowen@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Ann LaCasce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan McKendree</last_name>
      <phone>734-936-2635</phone>
      <email>mckendre@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Kaminski, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayo Clinic Clinical Trials ReferralOffice</last_name>
      <phone>507-538-7623</phone>
    </contact>
    <investigator>
      <last_name>Stephen Ansell, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maribeth Hohenstein</last_name>
      <phone>402-559-9053</phone>
      <email>mahohens@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Bociek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celeste Rojas</last_name>
      <phone>212-326-5736</phone>
      <email>CR2393@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ahmed Sawas, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital, The</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Hinds</last_name>
      <phone>513-686-3365</phone>
      <email>lmhinds@health-partners.org</email>
    </contact>
    <investigator>
      <last_name>Miguel Islas-Ohlmayer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Kane</last_name>
      <phone>216-844-8123</phone>
      <email>donna.kane1@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Paolo Caimi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Cameron</last_name>
      <phone>843-792-4486</phone>
      <email>cameroa@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Stuart, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Leary</last_name>
      <phone>864-255-1517</phone>
      <email>lisa_leary@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Howland Crosswell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Goetz</last_name>
      <phone>214-818-8325</phone>
      <email>erica.goetz@baylorhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Edward Agura, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Scott</last_name>
      <phone>804-628-1909</phone>
      <email>jscott@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Beata Holkova, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>June 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Hodgkin Disease</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Antigens, CD30</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>monomethylauristatin E</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Bendamustine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
